With a net asset value of over £1 billion, CBG is one of the UK’s leading family offices, whose overall portfolio includes pharma, biotech, med-tech, cleantech, real estate and other business interests. They have invested more than $400 million in Israel in direct investments and as an LP or GP in incubators and funds from early to late stage investments. CBG is also a leading shareholder and investor in various holdings and platforms, including Hadasit Bio Holdings (“HBL”), Xenia Venture Capital, Capital Nature Group and Trendlines.